<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162966</url>
  </required_header>
  <id_info>
    <org_study_id>KSMC-CCD-AFM-002</org_study_id>
    <nct_id>NCT02162966</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of High Dose Colistin</brief_title>
  <official_title>Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Saud Medical City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Saud Medical City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post
      antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa,
      Acinetobacterbaumannii, and Klebsiella pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety of high dose Colistin</measure>
    <time_frame>7 to 21 days after giving Colistin</time_frame>
    <description>Evaluate the safety of high dose Colistin to treat MDRO infection in critically ill patients.
The safety of high dose Colistin will be determined by number of participants whom renal function will be deviated from the baseline after administering high dose of Colistin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>7 days after the end of therapy or at 28 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation free days</measure>
    <time_frame>28 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>28 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>A day 7 and at the end of therapy</time_frame>
    <description>whole body cultures will be done at day 7 of treatment and at the end of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>High Dose Colistin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose colistin protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Colistin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose of colistin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Colistin</intervention_name>
    <description>High Dose Colistin</description>
    <arm_group_label>High Dose Colistin</arm_group_label>
    <other_name>colistin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Dose Colistin</intervention_name>
    <description>Standard Dose Colistin</description>
    <arm_group_label>Standard Dose Colistin</arm_group_label>
    <other_name>Colistin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               1. Patient age more than or equal 18 years old.

               2. Patient has clinical signs and symptoms of infection with suspected or proven
                  infection due to Carbapenem resistant microorganism.

               3. Patient was started with Empirical therapy of Colistin and positive MDRO within 5
                  days of empirical therapy.

          -  Exclusion Criteria:

               1. Patient age less than 18 years.

               2. Pregnant patient.

               3. If received Colistin treatment for less than 72 hours.

               4. Renal Replacement Therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed F Mady, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Saud Medical City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed F Mady, PhD</last_name>
    <phone>00966547060770</phone>
    <email>afmady@ksmc.med.sa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Basheer M Abdelrahman, pharmD</last_name>
    <phone>00966563516815</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King Saud Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>00966</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed F Mady, PhD</last_name>
      <phone>00966547060770</phone>
      <email>afmady@ksmc.med.sa</email>
    </contact>
    <investigator>
      <last_name>Ahmad F Mady, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Basheer A Abdelrahman, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammed A Rana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar A Ramadan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdulrahman M Al-Harthy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colistin</keyword>
  <keyword>ICU</keyword>
  <keyword>critical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

